Neurocrine Biosciences | NBIX - 销售成本



金融业
股票价格
USD
资产
USD 5.36B
现金及等价物
USD 332.4M
销售成本
USD 39.4M
流动资产
USD 1.64B
流动负债
USD 874.5M
债务
USD 406.2M
EBIT
USD 219.9M
EBITDA
USD 193.3M
员工
1.8K
EPS每股收益
USD 2.85
股本和储备
USD 3.69B
销售毛利
USD 800.7M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 15.36B
净收入
USD 144.4M
营业费用
USD 739.1M
营业利润
USD 219.9M
普通股股本
USD 100.55M
PE价格收益
22.1
税前利润
USD 246.8M
销售收入
USD 959M
销售和管理费用
USD 383.1M
股票
USD 104.2M
贸易债权人
USD 691.3M
应收帐款人
USD 887M


销售成本 更改 日
AbbVie USD 4.29B 73M 2026-06
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
Agios Pharmaceuticals USD 1.32M 560K 2026-03
ALKERMES USD 120.7M 47.44M 2026-06
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amgen USD 1.87B 271M 2026-06
Biogen USD 945.1M 147.6M 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Cytokinetics USD 5.59M 5.43M 2026-06
Exelixis USD 20.66M 704K 2026-06
Gilead Sciences USD 1000M 445M 2026-06
Halozyme Therapeutics USD 108.68M 67K 2026-06
Incyte USD 104.96M 457K 2026-06
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Pfizer USD 4.09B 498M 2026-06
Prothena USD 28.94M 11.58M 2025-09
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Repligen USD 94.09M 8.12M 2026-06
Rigel Pharmaceuticals USD 8.03M 5.22M 2024-09
Sarepta Therapeutics USD 150.1M 40.64M 2026-06
Teva Pharmaceutical Industries USD 1.98B 30M 2026-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vertex Pharmaceuticals USD 489.2M 96.4M 2026-06